|
Cardiovascular Pharmacology
Citations 261-270 of 1154 total displayed.
|
Past content
(since Jan 1999):
|
- Molecular Cardiology
In Vivo Evidence for Nitric Oxide–Mediated Calcium-Activated Potassium-Channel Activation During Human Endotoxemia
- Peter Pickkers, Mirrin J. Dorresteijn, Martijn P.W.J.M. Bouw;, Johannes G. van der Hoeven, and Paul Smits
Circulation 2006;114:414-421; published online before print as doi:10.1161/CIRCULATIONAHA.105.590232
[Abstract]
[Full text]
- Articles
In Vivo Evidence for Nitric Oxide-Mediated Calcium-Activated Potassium-Channel Activation During Human Endotoxemia
- Peter Pickkers, Mirrin J. Dorresteijn, Martijn P.W.J.M. Bouw, Johannes G. van der Hoeven, and Paul Smits
Circulation published July 24, 2006, doi:10.1161/CIRCULATIONAHA.105.590232
[Abstract]
- Arrhythmia/Electrophysiology
Effects of the Gap Junction Modifier Rotigaptide (ZP123) on Atrial Conduction and Vulnerability to Atrial Fibrillation
- Jose M. Guerra, Thomas H. Everett, IV, Ken W. Lee, Emily Wilson, and Jeffrey E. Olgin
Circulation 2006;114:110-118; published online before print as doi:10.1161/CIRCULATIONAHA.105.606251
[Abstract]
[Full text]
- Myocardial Protection and Vascular Biology
Role Of Endothelin-1 and Nitric Oxide Bioavailability in Transplant-Related Vascular Injury: Comparative Effects of Rapamycin and Cyclosporine
- Danny Ramzy, Vivek Rao, Laura C. Tumiati, Ning Xu, Santiago Miriuka, Diego Delgado, and Heather J. Ross
Circulation 2006;114:I-214-219I-, doi:10.1161/CIRCULATIONAHA.105.000471
[Abstract]
[Full text]
- Articles
Effects of the Gap Junction Modifier Rotigaptide (ZP123) on Atrial Conduction and Vulnerability to Atrial Fibrillation
- Jose M. Guerra, Thomas H. Everett, IV, Ken W. Lee, Emily Wilson, and Jeffrey E. Olgin
Circulation published July 3, 2006, doi:10.1161/CIRCULATIONAHA.105.606251
[Abstract]
- Editorials
Cardiology Is Flow
- Yoram Richter and Elazer R. Edelman
Circulation 2006;113:2679-2682, doi:10.1161/CIRCULATIONAHA.106.632687
[Full text]
- Editorials
Does Aspirin Reduce the Benefit of an Angiotensin-Converting Enzyme Inhibitor?: Choosing Between the Scylla of Observational Studies and the Charybdis of Subgroup Analysis
- Pardeep Jhund and John J.V. McMurray
Circulation 2006;113:2566-2568, doi:10.1161/CIRCULATIONAHA.106.629212
[Full text]
- Heart Failure
Aspirin Use and Outcomes in a Community-Based Cohort of 7352 Patients Discharged After First Hospitalization for Heart Failure
- Finlay A. McAlister, William A. Ghali, Yanyan Gong, Jiming Fang, Paul W. Armstrong, and Jack V. Tu
Circulation 2006;113:2572-2578; published online before print as doi:10.1161/CIRCULATIONAHA.105.602136
[Abstract]
[Full text]
- Articles
Aspirin Use and Outcomes in a Community-Based Cohort of 7352 Patients Discharged After First Hospitalization for Heart Failure
- Finlay A. McAlister, William A. Ghali, Yanyan Gong, Jiming Fang, Paul W. Armstrong, and Jack V. Tu
Circulation published May 30, 2006, doi:10.1161/CIRCULATIONAHA.105.602136
[Abstract]
- Arrhythmia/Electrophysiology
Focal Pharmacological Modulation of Atrioventricular Nodal Conduction via Implantable Catheter: A Novel Therapy for Atrial Fibrillation?
- Daniel C. Sigg, Prasanga Hiniduma-Lokuge, James A. Coles, Jr, Phillip Falkner, Rebecca Rose, Jon F. Urban, and Michael R. Ujhelyi
Circulation 2006;113:2383-2390; published online before print as doi:10.1161/CIRCULATIONAHA.105.609420
[Abstract]
[Full text]
|
|
